Radius Health Stock Forecast, Price & News

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have decreased by 57.3% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19.

Are investors shorting Radius Health?

Radius Health saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 7,770,000 shares, an increase of 17.7% from the December 15th total of 6,600,000 shares. Based on an average trading volume of 2,045,100 shares, the short-interest ratio is presently 3.8 days.
View Radius Health's Short Interest.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Radius Health.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to the consensus estimate of $61.40 million. During the same quarter in the prior year, the firm earned ($0.14) EPS.
View Radius Health's earnings history.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210 million-$220 million, compared to the consensus revenue estimate of $242.26 million.

What price target have analysts set for RDUS?

5 Wall Street analysts have issued 1 year price objectives for Radius Health's stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Radius Health's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:

• George Kelly Martin, President, Chief Executive Officer & Director
• Steven Helwig, CFO, Treasurer & Chief Accounting Officer
• Bruce Mitlak, Chief Medical Officer
• Averi Price, Secretary, Chief Compliance Officer & VP
• Chhaya Shah, Chief Business Officer & Senior Vice President

Who are some of Radius Health's key competitors?

Some companies that are related to Radius Health include FibroGen (FGEN), Avid Bioservices (CDMO), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), ImmunoGen (IMGN), NGM Biopharmaceuticals (NGM), Keros Therapeutics (KROS), Innoviva (INVA), MorphoSys (MOR), ADC Therapeutics (ADCT), Rocket Pharmaceuticals (RCKT), PureTech Health (PRTC), Rani Therapeutics (RANI) and Axsome Therapeutics (AXSM).
View all of RDUS's competitors.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Radius Health stock include James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $6.86.

How much money does Radius Health make?

Radius Health has a market capitalization of $324.77 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109.21 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 310 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

Where are Radius Health's headquarters?

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.